Table 1 |
||||
|
SELDI-TOF MS protein peaks differentially expressed in paired sera from SJIA before and after therapy |
||||
| Before/after conventional therapy |
Before/after MRA |
|||
|
|
||||
| Mass (m/z) |
P |
Patients with visually distinct peaks/total no. of patients |
P |
Patients with visually distinct peaks/total no. of patients |
|
|
||||
| 4504 |
0.0001 |
0.005 |
||
| 4758 |
0.0005 |
0.0006 |
||
| 5739 |
0.0001 |
0.00000008 |
||
| 6441 |
0.00009 |
0.0001 |
||
| 6947 |
0.0005 |
0.003 |
||
| 9510 |
0.0007 |
6/8 |
0.00001 |
12/15 |
| 9725 |
0.00006 |
0.00001 |
||
| 11405 |
0.00001 |
8/8 |
0.000000003 |
14/15 |
| 11520 |
0.000007 |
8/8 |
0.000000001 |
14/15 |
| 11641 |
0.000005 |
8/8 |
0.0000000001 |
14/15 |
| 11718 |
0.0004 |
0.00002 |
||
| 11880 |
0.0002 |
0.0000006 |
||
| 12703 |
0.0006 |
7/8 |
0.04 |
6/15 |
| 20816 |
0.0002 |
7/8 |
0.01 |
9/15 |
| 22389 |
0.0002 |
0.00005 |
||
| 23627 |
0.0002 |
0.09 |
||
| 28734 |
0.0002 |
0.00006 |
||
| 33457 |
0.00001 |
6/8 |
0.00001 |
11/15 |
| 66637 |
0.0001 |
7/8 |
0.000009 |
11/15 |
| 74886 |
0.0006 |
0.00003 |
||
| 75622 |
0.0009 |
0.0001 |
||
| 76319 |
0.0008 |
0.00002 |
||
| 79216 |
0.0007 |
0.000003 |
||
|
|
||||
|
Differences between mass spectra of sera before and after conventional therapy. Sera from eight patients with SJIA who responded to conventional therapy were analyzed before and after therapy by SELDI-TOF MS using Ciphergen IMAC-3 copper chips. All samples were run in duplicate. Only variables with nonparametric P values of <0.001 are given. Of 282 spectral peaks identified, the 23 listed here had mean signal intensities significantly different (P < 0.001) before and after response to treatment. Proteins are listed according to mass/charge ratio. Visually distinct peaks (in bold type) refers to peaks that were clearly different between paired samples from before and after treatment upon visual inspection of the profiles, as shown in Fig. 1. The numbers of patients in whom these peaks were visually distinct are shown in columns 3 and 5. These peaks represent potential biomarkers of active disease. IMAC-3, immobilized metal affinity capture; MRA, humanized anti-IL-6 receptor monoclonal antibody; SELDI-TOF MS, surface-enhanced laser desorption/ionization time-of-flight mass spectrometry; SJIA, systemic juvenile idiopathic arthritis. |
||||
|
Miyamae et al. Arthritis Research & Therapy 2005 7:R746 doi:10.1186/ar1723 |
||||
